The relationship between sustained virological response (SVR) and early viral kinetics in patients receiving albinterferon-α-2b every 2 weeks (q2wk) or 4 weeks (q4wk) is depicted: (A) mean hepatitis C virus (HCV)-RNA reductions during the first 12 weeks of treatment; (B) relationship of first-phase viral decline with HCV-RNA level at day 3; relationships of second-phase slope of viral decline with HCV-RNA level at baseline (C) and day 3 (D).